BioCentury | Nov 1, 2018
Emerging Company Profile

Secarna’s next-gen oligos

...The company was established in 2015 by the founders and investors who launched antisense company Sterna Biologicals...
...Pharmaceuticals AB, Umea, Sweden Oligonucleotide Therapeutics Society, San Diego, Calif. Secarna Pharmaceuticals GmbH, Munich, Germany Sterna Biologicals...
...2,3-dioxygenase PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 Alicia Parker, Staff Writer Secarna Pharmaceuticals GmbH sterna biologicals GmbH & Co. KG Angiopoietin-like...
BioCentury | Mar 2, 2018
Clinical News

sterna's SB012 meets in Phase IIa data for UC

...SB012 is an enema formulation of a deoxyribozyme (DNAzyme)-based GATA binding protein 3 (GATA3) antagonist. sterna biologicals GmbH & Co. KG...
...at day 56, endoscopic Mayo score, pharmacokinetics and safety Status: Phase IIa data Milestone: NA Jennie Walters sterna biologicals GmbH & Co. KG GATA...
Items per page:
1 - 2 of 2
BioCentury | Nov 1, 2018
Emerging Company Profile

Secarna’s next-gen oligos

...The company was established in 2015 by the founders and investors who launched antisense company Sterna Biologicals...
...Pharmaceuticals AB, Umea, Sweden Oligonucleotide Therapeutics Society, San Diego, Calif. Secarna Pharmaceuticals GmbH, Munich, Germany Sterna Biologicals...
...2,3-dioxygenase PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 Alicia Parker, Staff Writer Secarna Pharmaceuticals GmbH sterna biologicals GmbH & Co. KG Angiopoietin-like...
BioCentury | Mar 2, 2018
Clinical News

sterna's SB012 meets in Phase IIa data for UC

...SB012 is an enema formulation of a deoxyribozyme (DNAzyme)-based GATA binding protein 3 (GATA3) antagonist. sterna biologicals GmbH & Co. KG...
...at day 56, endoscopic Mayo score, pharmacokinetics and safety Status: Phase IIa data Milestone: NA Jennie Walters sterna biologicals GmbH & Co. KG GATA...
Items per page:
1 - 2 of 2